Amar Desai

641 posts

Amar Desai

Amar Desai

@desailabcwru

Stem cells and drug development, Case Comprehensive Cancer Center @cwru. https://t.co/wmeP7B4Fvc.

Cleveland, OH Katılım Ocak 2013
865 Takip Edilen665 Takipçiler
Amar Desai retweetledi
CWRU School of Medicine
CWRU School of Medicine@CWRUSOM·
A paper titled published in the @PNASNews from the laboratories of @CWRUSOM professors Andrew Pieper and Sanford Markowitz was awarded the 2025 PNAS Cozzarelli Prize in Biomedical Sciences. Learn more: brnw.ch/21x0QVd
English
0
2
4
415
Amar Desai retweetledi
Case Western Reserve
Case Western Reserve University has been named one of the world’s top universities, ranking 25th globally in @TIME's inaugural World’s Best Universities list! brnw.ch/21wZwU0
English
2
30
139
23.5K
Amar Desai retweetledi
Jason Shepherd
Jason Shepherd@JasonSynaptic·
My @NIH study section will not meet tomorrow because of the government shutdown. This may seem trivial but rescheduling these meetings will delay funding decisions for months to even a year! Let alone the uncertainty of what the FY26 budget will be. Awful for US scientists! 😓
English
8
22
189
47.3K
Amar Desai
Amar Desai@desailabcwru·
Excited to be in beautiful San Juan for the Department of Energy @ENERGY “1-2-3 to Cesium Free” workshop. Great talks on alternatives to cesium radiation sources in biomedical research- very relevant to our work @caseccc. Looking forward to continued engagement with this group!
Amar Desai tweet media
English
0
0
1
103
Amar Desai retweetledi
Case Comp Cancer Ctr
Case Comp Cancer Ctr@caseccc·
We had a full house today as we welcomed @BDBiosciences to launch our brand new FACSDiscover A8 Cell Analyzer! We’re proud to be one of the first institutions in the Midwest to bring this technology in-house and can’t wait to see the discoveries it helps unlock.
Case Comp Cancer Ctr tweet mediaCase Comp Cancer Ctr tweet media
English
0
1
2
324
Amar Desai retweetledi
ABME
ABME@ABMEjournal·
Breathing shouldn’t be a battle, but for those with idiopathic pulmonary fibrosis (IPF), it often is. To improve the lives of patients living with this progressive, deadly lung disease, researchers explored a new way to deliver two leading IPF medications – Nintedanib (NTB) and Pirfenidone (PFD) – with fewer side effects and less frequent dosing. By embedding these drugs in microparticles made from beta-cyclodextrin polymers, the team achieved: 🔹 Sustained drug release that maintained therapeutic levels of NTB for over 70 hours 🔹 Significant reductions in inflammation linked to fibrotic lung injury 🔹 Fewer required doses compared to daily NTB regimens This novel delivery system could make a hard-to-treat disease just a little easier to live with. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: link.springer.com/article/10.100… 𝗦𝘁𝘂𝗱𝘆: Sustained Release of Antifibrotic Nintedanib from Polymer Microparticles Reduces Dosing Frequency While Reducing Inflammation in Preclinical Models of Idiopathic Pulmonary Fibrosis 𝗔𝘂𝘁𝗵𝗼𝗿𝘀: Emmanuel Einyat Opolot, Filip Goshevski, Rahul Chaudhary, Jessica A. Kilgore, Noelle S. Williams, Horst A. von Recum, and @desailabcwru @cwru @CaseEngineer @CWRUSOM @CWRUBME @UTSWMedCenter 𝗦𝘂𝗯𝗺𝗶𝘁 𝘆𝗼𝘂𝗿 𝗺𝗮𝗻𝘂𝘀𝗰𝗿𝗶𝗽𝘁: link.springer.com/journal/10439
ABME tweet media
English
0
1
1
162
Amar Desai
Amar Desai@desailabcwru·
6/ We’re excited to keep building on this to make existing IPF therapies more effective, more tolerable, and easier to use. Check it out here! link.springer.com/article/10.100…
English
0
0
3
78
Amar Desai
Amar Desai@desailabcwru·
5/ Using a β-cyclodextrin microparticle platform, we developed a slow-release formulation of nintedanib to reduce dosing frequency. The formulation: ▸ Showed sustained release in vitro ▸ Was well-tolerated in mice ▸ 2 low-dose injections ≈ 14 days of high-dose drug
English
1
0
2
94
Amar Desai
Amar Desai@desailabcwru·
1/Excited to share a new team science publication from our lab @caseccc in collaboration with @HA_vonRecum in @CWRUbme. A quick thread outlining our studies...
English
2
1
6
268
Isabel Bravo
Isabel Bravo@Isabel_M_Bravo·
My F31 is gone. It’s a small loss in the scheme of things but I was really proud of it.
NIH@NIH

Today #NIH is terminating more than $250 million in funding—including more than 400 grants—to Columbia University following directives from the Trump Administration’s Joint Task Force to Combat Anti-Semitism. The cancellations are due to Columbia University’s continued inaction in the face of persistent harassment of Jewish students.

English
38
75
790
115.9K
Amar Desai
Amar Desai@desailabcwru·
Bittersweet saying goodbye to Rahul Chaudhary. From an overly earnest undergrad, to seasoned research technician, to medical school in the fall! Very proud of him, and grateful for his time in our lab. @caseccc
Amar Desai tweet media
English
0
0
6
348
Amar Desai
Amar Desai@desailabcwru·
@costinebartell @NIH I’m so sorry! Side note- we started studying impacts of TBI on hematopoiesis and HSC function, we should chat!
English
0
0
12
2K
Amar Desai
Amar Desai@desailabcwru·
Just found out the study section scheduled to review my grant today was canceled. I spent three months writing it, representing five years of work from my lab. Gutted. @NIH
English
84
378
2.1K
169.1K
Amar Desai
Amar Desai@desailabcwru·
@doctorBobG @NIH I’m really sorry to hear that. Been spiraling all day thinking about the ramifications.
English
1
0
26
3K
Prof. Robert Gregg, Ph.D.
Prof. Robert Gregg, Ph.D.@doctorBobG·
@desailabcwru @NIH Mine too, study section was supposed to meet yesterday. R01 renewal in limbo while my remaining funds burn away. This clinical trial may never happen now.
English
1
7
56
4.6K
Amar Desai
Amar Desai@desailabcwru·
@Aaron_j_Norris @NIH I guess this saves me hours of refreshing ERA Commons over the next few days?
English
0
0
6
3.6K